Allogene Therapeutics ALLO incurred a lack of 28 cents per share in fourth-quarter 2024, narrower than the Zacks Consensus Estimate of a lack of 34 cents. Within the year-ago interval, the corporate had incurred a lack of 51 cents per share.
See the Zacks Earnings Calendar to remain forward of market-making information.
ALLO didn’t generate revenues throughout the reported quarter. The Zacks Consensus Estimate for fourth-quarter gross sales was pegged at $0.07 million. Within the year-ago interval, the corporate recorded revenues of $0.02 million.
12 months thus far, shares of Allogene have misplaced 11% in opposition to the industry’s 6% development.
Picture Supply: Zacks Funding Analysis
Extra on ALLO’s This fall Outcomes
Analysis & improvement (R&D) bills totaled $45 million, down 18% from the year-ago quarter’s degree.
Basic and administrative (G&A) bills declined 10% yr over yr to $15.5 million.
As of Dec. 31, 2024, Allogene had $373.1 million of money, money equivalents and investments, in contrast with $403.4 million as of Sept. 30, 2024. The corporate claims that its money runway will fund operations into the second half of2026.
Full-12 months Outcomes
In 2024, Allogene recorded complete revenues of $0.2 million, down 77% yr over yr.
The corporate reported a lack of $1.32 per share for the yr, narrower than the year-ago interval’s lack of $2.09.
ALLO’s 2025 Steerage
Allogene anticipates working bills for the complete yr to be round $250 million, together with non-cash stock-based compensation bills of almost $50 million.
Money burn for 2025 is anticipated to be round $170 million.
Updates on ALLO’s Pipeline
Allogene’s essential focus is on the pivotal part II ALPHA3 research, which is evaluating lead drug cema-cel as a possible first-line remedy for newly recognized and handled massive B cell lymphoma (LBCL) sufferers who’re prone to relapse and wish additional remedy. Whereas the corporate expects top-line information from this research by 2026-end, a regulatory submission for a similar is deliberate for 2027.
Final month, Allogene printed up to date information from the now deprioritized part I ALPHA and ALPHA2 research, which evaluated cema-cel in third-line LBCL. Knowledge from these research confirmed that remedy with cema-cel is efficient in sufferers who’ve low illness burden. In our opinion, these outcomes present extra confidence in administration’s pivot to develop cema-cel as a front-line remedy.
The lymphodepletion choice and futility evaluation from the ALPHA3 research is anticipated round mid-2025. This evaluation will present perception into whether or not the corporate’s strategy may meet its goals.
Allogene can also be planning to discover the potential of allogeneic CAR-T cell therapies in autoimmune ailments. On this regard, it plans to start out an early-stage research with a brand new candidate, ALLO-329, in lupus/systemic lupus erythematosus (SLE) indication in mid-2025 and expects to have proof-of-concept by 2025-end.
In November, Allogene reported new information from the part I TRAVERSE research, evaluating ALLO-316 in sufferers with superior or metastatic renal cell carcinoma (RCC) who’ve progressed following remedy with an immune checkpoint inhibitor and VEGF-targeting remedy. Knowledge from the research confirmed that sufferers with excessive CD70 expression who have been infused with the drug achieved an total response fee of fifty% and a confirmed response fee of 33%. Based mostly on this information, the FDA has granted Regenerative Medication Superior Remedy designation to ALLO-316 in superior or metastatic RCC. Extra information from this research is anticipated in mid-2025.
ALLO’s Zacks Rank
Allogene presently has a Zacks Rank #3 (Maintain).
Allogene Therapeutics, Inc. Worth
Allogene Therapeutics, Inc. price | Allogene Therapeutics, Inc. Quote
Key Picks Amongst Biotech Shares
Some top-ranked shares from the sector are ANI Prescription drugs ANIP, CytomX Therapeutics CTMX and 89bio ETNB. Whereas ANIP and CTMX sport a Zacks Rank #1 (Robust Purchase) every, ETNB presently carries a Zacks Rank #2 (Purchase). You may see the complete list of today’s Zacks #1 Rank stocks here.
Previously 60 days, estimates for ANI Prescription drugs’ 2025 earnings per share (EPS) have risen from $5.54 to $6.31. EPS estimates for 2026 have elevated from $6.75 to $6.90 throughout the identical interval. 12 months thus far, shares of ANIP have risen 11%.
ANIP’s earnings beat estimates in every of the trailing 4 quarters, delivering a median shock of 17.32%.
Previously 60 days, estimates for CytomX Therapeutics’ 2025 loss per share have narrowed from 31 cents to 10 cents. Throughout the identical timeframe, loss per share estimates for 2026 have narrowed from 65 cents to 50 cents. 12 months thus far, shares of CytomX have misplaced almost 43%.
CTMX’s earnings beat estimates in three of the trailing 4 quarters and missed the mark as soon as, delivering a median shock of 180.70%.
Previously 60 days, estimates for 89bio’s 2025 loss per share have narrowed from $3.19 to $1.98. Throughout the identical timeframe, loss per share estimates for 2026 have narrowed from $2.49 to $2.15. 12 months thus far, shares of ETNB have gained about 5%.
89bio’s earnings missed estimates in three of the trailing 4 quarters and beat the mark as soon as, delivering a detrimental common shock of 46.18%.
Zacks’ Analysis Chief Names “Inventory Most More likely to Double”
Our group of consultants has simply launched the 5 shares with the best likelihood of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This prime decide is among the many most progressive monetary corporations. With a fast-growing buyer base (already 50+ million) and a various set of leading edge options, this inventory is poised for large positive factors. In fact, all our elite picks aren’t winners however this one may far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report
Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report
89BIO (ETNB) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
